IP Library Granted Patent US 12,178,789
Granted Patent B2
US 12,178,789 · App. 18/530,782 · Granted Dec 31, 2024

Stress test and treatment of chronic kidney disease

Inventors: Donald Jeffrey Keyser (Southlake, TX); Alvaro F. Guillem (Lantana, TX); Bhupinder Singh (Phoenix, AZ); Richard A. Zager (Seattle, WA)
Assignee: Renibus Therapeutics, Inc.
A61K31/12G01N33/6893G01N2800/7009
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,178,789
App. No.
18/530,782
Granted
Dec 31, 2024
Kind
B2
Abstract

The present invention involves a novel method for treatment of chronic kidney disease comprising administering a compound that induces a stress protein response in a patient, and administering a potent antioxidant if the patent's response is below a predefined level. It also involves a quantitative measure for determining a patient's antioxidant reserve capacity.

Claims (10)

1. A method comprising:

(a) administering a compound to a patient, wherein the compound is a protoporphyrin or mesoporphyrin, which stimulates production of one or more antioxidant proteins in the patient;

(b) obtaining one or more body fluid samples from a patient; and

(c) measuring the level of the one or more anti-oxidant proteins produced in the patient.

2. The method of claim 1 , wherein the compound is a transient oxidant stress inducer.

3. The method of claim 1 , wherein compound is a metal protoporphyrin.

4. The method of claim 3 , wherein the metal protoporphyrin is tin, cobalt, or zinc protoporphyrin.

5. The method of claim 1 , wherein the anti-oxidant proteins comprise one or more of HO-1, ferritin, p21, or NQO1.

6. The method of claim 1 , wherein the level of production of the one or more anti-oxidant proteins is measured before step (a), and the level of expression of the one or more anti-oxidant proteins measured in step (c) is compared to the level of expression measured before step (a).

7. The method of claim 1 , wherein the measured level of antioxidant proteins provides a quantitative measure of the anti-oxidant reserves of the patient.

Assignments (2)
SECURITY INTEREST Recorded Jun 4, 2026
From: RENIBUS THERAPEUTICS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 074858/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2023
From: KEYSER, DONALD JEFFREY; GUILLEM, ALVARO F.; SINGH, BHUPINDER; ZAGER, RICHARD A.
To: RENIBUS THERAPEUTICS, INC.
Reel/Frame 065860/0832 →
Continuity (3)
Division 17210205 · Mar 23, 2021
Provisional Application 62993446 · Mar 23, 2020
Related Publication 20240108589A1 · Apr 4, 2024